Search clinical trials for: ACH126, 433

Total 727 results

Nirsum Labs
National Institute on Drug Abuse (NIDA)

Recruiting

Single Ascending Dose Study of NRS 033 in Healthy Volunteers

Healthy Volunteers

United States
Rhythm Pharmaceuticals, Inc.

Active, not recruiting

Long Term Extension Trial of Setmelanotide

Obesity Associated With Defects in Leptin-melanocortin Pathway

United States, Netherlands, Canada, Germany, United Kingdom, France, Greece, Spain
Otonomy, Inc.

Completed

OTO-413 in Subjects With Speech-in-Noise Hearing Impairment

Sensorineural Hearing Loss

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

End Stage Renal Disease
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites

Hypertension | Congestive Heart Failure

Switzerland
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Chronic Pain
Amgen

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain

Osteoarthritis
Takeda

Completed

A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects

Clinical Pharmacology

Japan
Kaken Pharmaceutical
Dow Pharmaceutical Sciences

Completed

A Study to Determine the Safety, Tolerability and Efficacy of KP-413 in Subjects With Atopic Dermatitis(AD)

Atopic Dermatitis

United States
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ABT-436 in Healthy Adults

Healthy

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder

Depressive Disorder | Depression | Major Depressive Disorder
Amgen

Completed

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Obesity

United States
AbbVie

Completed

Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects

HCV Infection
Purdue University
Almond Board of California

Completed

Metabolic Effects of Almond in the Longer-term Study (MEAL)

Obesity

United States
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Dose of ABT-333 in Healthy Male Adults

HCV Infections

Japan
Abbott

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

HCV Infection

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

Vasomotor Symptoms

United States
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
Rhythm Pharmaceuticals, Inc.

Completed

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

Overweight and Obesity

United States
Rhythm Pharmaceuticals, Inc.

Completed

Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity

Leptin Receptor Deficiency Obesity

Netherlands, Germany, United Kingdom, Canada, France, Réunion
Cytokinetics

Withdrawn

Omecamtiv Mecarbil Post-trial Access Study

Chronic Heart Failure With Reduced Ejection Fraction
Kowa Company, Ltd.

Completed

Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC

Hepatic Neoplasm Malignant Recurrent

Japan
AbbVie

Completed

Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder

Major Depressive Disorder
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France
Bial - Portela C S.A.

Completed

Bioavailability Study of BIA 5-453

Hypertension | Congestive Heart Failure

France
Rhythm Pharmaceuticals, Inc.

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers

Overweight | Obese
Millennium Pharmaceuticals, Inc.

Withdrawn

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Advanced Nonhematologic Malignancies

United States
Coloplast A/S

Completed

Investigate Bladder and Prostate During Emptying With Intermittent Catheter

Urinary Function

Denmark
University of Oulu

Unknown

The Effect of Timing on Orthodontic Treatment

Malocclusion, Angle Class II
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Obesity

United States
Chang Gung Memorial Hospital

Completed

Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression

Parkinson Disease
Chang Gung Memorial Hospital

Completed

Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects

Healthy
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States, New Zealand
Chong Kun Dang Pharmaceutical

Completed

Pharmacokinetics and Safety Profile of CKD-333

Hypertension | Dyslipidemias

Korea, Republic of
Rhythm Pharmaceuticals, Inc.

Completed

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
OBI Pharma, Inc

Completed

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

Metastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric Cancer

Taiwan
Cytokinetics

Withdrawn

Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Heart Failure
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Renal Impairment

United States, New Zealand
Cytokinetics

Completed

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

Healthy Volunteer

Japan
Takeda

Completed

Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis

Japan
Aegerion Pharmaceuticals, Inc.

Completed

Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Familial Hypercholesterolemia

United States, Canada, Italy, South Africa
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Hypertension

France
Rhythm Pharmaceuticals, Inc.

Completed

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Bardet Biedl Syndrome (BBS) | Alström Syndrome (AS)

United States, United Kingdom, France, Canada, Puerto Rico, Spain
Takeda

Completed

Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)

Non-erosive Gastroesophageal Reflux Disease

Japan
Bial - Portela C S.A.

Completed

Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453

Hypertension | Chronic Heart Failure

3

Subscribe